A Phase 1 interventional study of BIBW 2992 and BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly. The MTD will provide dosing recommendation for subsequent phase II trials in patients with metastatic cancer.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 70 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
Drug: BIBW 2992 · Drug: BIBF 1120
Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities
Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.
Time frame: first treatment cycle, up to 28 days
Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1
The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions
Time frame: 6 weeks
Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
Time frame: First treatment administration until cut-off date of 02Oct2014; up to 336 days
Changes in Safety Laboratory Parameters
Changes in safety laboratory Parameters reported as adverse events
Time frame: First treatment administration until cut-off date of 02 October 2014, up to 336 days
Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)
Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28)
Time frame: Day 8, Day 15, Day 22 and Day 28
Trough Plasma Concentration of Afatinib at Steady State
C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27.
Time frame: Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
Objective Response (OR) During the Expansion Phase
OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'.
Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Disease Control (DC) During the Expansion Phase
DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD. CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions . All lymph nodes must be non-pathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD. SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.
Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Stable Disease for at Least 12 Weeks During the Expansion Phase
SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.
Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Percentage Change in the Tumour Size From Baseline During the Expansion Phase
Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.
Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Trial consisted of a dose-escalation phase (to determine the maximum tolerated dose (MTD) of treatments administered concomitantly) and an expansion phase(to assess the safety and the preliminary anti-tumour activity of the combination therapy at the previously determined MTD in patients with non-small cell lung cancer or pancreatic adenocarcinoma)
| Milestone | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 3 | 3 | 3 | 8 | 3 | 7 | 6 | 6 | 18 | 7 |
| Completed | 6 | 2 | 3 | 3 | 6 | 3 | 6 | 4 | 4 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 2 | 2 | 18 | 7 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 14 | 5 |
| Withdrew: Dose limiting or dose reducing toxicity | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Other adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Refused to continue taking trial med. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Reason other than those specified above | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.
| percentage of participants | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently |
|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increased | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 33.3 | 0.0 | 0.0 | 0.0 |
| Aspartate aminotransferase increased | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Blood creatinine increased | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | 0.0 | 16.7 | 0.0 |
| Dehydration | 0.0 | 33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 |
| Diarrhoea | 0.0 | 33.3 | 0.0 | 0.0 | 25.0 | 33.3 | 0.0 | 16.7 | 0.0 |
| Hepatocellular injury | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | 0.0 | 16.7 | 0.0 |
| Renal failure acute | 0.0 | 66.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hepatotoxicity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 |
The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions
| percentage of participants | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete response | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Partial response | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17.6 | 0.0 |
| Stable disease | 66.7 | 66.7 | 66.7 | 33.3 | 71.4 | 100 | 66.7 | 83.3 | 100.0 | 70.6 | 33.3 |
| Progressive disease | 33.3 | 33.3 | 33.3 | 66.7 | 28.6 | 0.0 | 33.3 | 16.7 | 0.0 | 11.8 | 66.6 |
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
| participants | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CTCAE Grade 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| CTCAE Grade 2 | 2 | 0 | 1 | 2 | 1 | 0 | 2 | 4 | 0 | 7 | 2 |
| CTCAE Grade 3 | 1 | 2 | 2 | 1 | 5 | 2 | 4 | 2 | 3 | 7 | 2 |
| CTCAE Grade 4 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 |
| CTCAE Grade 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 |
Changes in safety laboratory Parameters reported as adverse events
| participants | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increased | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 1 | 1 |
| Aspartate aminotransferase increased | 1 | 1 | 1 | 0 | 3 | 3 | 1 | 2 | 1 | 1 | 2 |
| Blood creatinine increased | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Blood alkaline phosphatase increased | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood bilirubin increased | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Troponin increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 |
| Blood creatinine phosphokinase increased | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood fibrinogen increased | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hepatic enzymes increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28)
| nanogram/millilitre/milligram (ng/mL/mg) | Nintedanib 150 mg +Afatinib 30 mg- Continuously | Nintedanib 150 mg +Afatinib 40 mg- Intermittently |
|---|---|---|
| Cpre,ss,15,norm (N= 6, 7) | 0.122 ± 155 | 0.0731 ± 92.2 |
| Cpre,ss,29,norm (N= 6, 6) | 0.0948 ± 136 | 0.0755 ± 148 |
| Cpre,ss,43,norm (N= 5, 6) | 0.112 ± 125 | 0.0762 ± 79.7 |
| Cpre,ss,55,norm (N= 8, NA) | 0.0797 ± 247 | NA ± NA |
C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27.
| nanogram/millilitre (ng/mL) | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently |
|---|---|---|
| Cpre,ss,15 (N= 6, NA) | 15.5 ± 62.0 | NA ± NA |
| Cpre,ss,22 (N= 6, NA) | 19.0 ± 56.5 | NA ± NA |
| Cpre,ss,28 (N= 8, NA) | 19.1 ± 63.3 | NA ± NA |
| C24,7 (N= NA, 6) | NA ± NA | 19.6 ± 127.0 |
| C24,13 (N= NA, 5) | NA ± NA | 11.5 ± 76.4 |
| C24,27 (N= NA, 2) | NA ± NA | 30.5 ± 21.9 |
OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'.
| percentage of participants | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|
| Yes | 22.2 | 0.0 |
| No | 72.2 | 85.7 |
| Missing | 5.6 | 14.3 |
DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD. CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions . All lymph nodes must be non-pathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD. SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.
| percentage of participants | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|
| Yes | 83.3 | 28.6 |
| No | 11.1 | 57.1 |
| Missing | 5.6 | 14.3 |
SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.
| percentage of participants | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|
| Yes | 44.4 | 0.0 |
| No | 50.0 | 85.7 |
| Missing | 5.6 | 14.3 |
Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.
| participants | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|
| >=20% | 1 | 3 |
| >=0% and <20% | 4 | 3 |
| >-30% and <0% | 6 | 0 |
| <-30% | 5 | 0 |
Collected over First treatment administration until cut-off date of 02Oct2014; up to 336 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib 150 mg +Afatinib 30 mg - Continuously | — | 3/6 (50%) | 6/6 (100%) |
| Nintedanib 150 mg +Afatinib 40 mg - Continuously | — | 3/3 (100%) | 3/3 (100%) |
| Nintedanib 200 mg +Afatinib 10 mg - Continuously | — | 1/3 (33.3%) | 3/3 (100%) |
| Nintedanib 200 mg +Afatinib 20 mg - Continuosly | — | 0/3 (0%) | 3/3 (100%) |
| Nintedanib 200 mg +Afatinib 30 mg - Continuously | — | 7/8 (87.5%) | 8/8 (100%) |
| Nintedanib 200 mg +Afatinib 40 mg - Continuously | — | 3/3 (100%) | 3/3 (100%) |
| Nintedanib 150 mg +Afatinib 40 mg - Intermittently | — | 1/7 (14.3%) | 7/7 (100%) |
| Nintedanib 200 mg +Afatinib 30 mg - Intermittently | — | 1/6 (16.7%) | 6/6 (100%) |
| Nintedanib 200 mg +Afatinib 40 mg - Intermittently | — | 4/6 (66.7%) | 6/6 (100%) |
| NSCLC | — | 7/18 (38.9%) | 18/18 (100%) |
| Pancreatic Adenocarcinoma | — | 3/7 (42.9%) | 6/7 (85.7%) |
| Event | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuosly | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/3 | 0/3 | 0/3 | 3/8 | 1/3 | 1/7 | 1/6 | 0/6 | 2/18 | 1/7 |
| HyperthermiaGeneral disorders | 0/6 | 1/3 | 0/3 | 0/3 | 0/8 | 0/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| Oedema peripheralGeneral disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/8 | 1/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| Bile duct obstructionHepatobiliary disorders | 0/6 | 0/3 | 1/3 | 0/3 | 0/8 | 0/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| CholangitisHepatobiliary disorders | 0/6 | 1/3 | 1/3 | 0/3 | 0/8 | 1/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| CholecystitisHepatobiliary disorders | 0/6 | 1/3 | 0/3 | 0/3 | 0/8 | 0/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| Blood creatinine increasedInvestigations | 0/6 | 0/3 | 0/3 | 0/3 | 0/8 | 1/3 | 0/7 | 1/6 | 0/6 | 0/18 | 1/7 |
| DehydrationMetabolism and nutrition disorders | 2/6 | 0/3 | 0/3 | 0/3 | 1/8 | 0/3 | 0/7 | 1/6 | 0/6 | 2/18 | 0/7 |
| Ischaemic strokeNervous system disorders | 0/6 | 1/3 | 0/3 | 0/3 | 0/8 | 0/3 | 0/7 | 0/6 | 0/6 | 0/18 | 0/7 |
| Renal failure acuteRenal and urinary disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/8 | 1/3 | 0/7 | 0/6 | 2/6 | 0/18 | 0/7 |
| Event | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuosly | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aphthous stomatitisGastrointestinal disorders | 0/6 | 1/3 | 0/3 | 0/3 | 1/8 | 3/3 | 0/7 | 0/6 | 1/6 | 0/18 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 6/6 | 3/3 | 3/3 | 3/3 | 8/8 | 3/3 | 6/7 | 6/6 | 6/6 | 14/18 | 6/7 |
| NauseaGastrointestinal disorders | 4/6 | 3/3 | 2/3 | 3/3 | 4/8 | 2/3 | 4/7 | 3/6 | 5/6 | 12/18 | 3/7 |
| VomitingGastrointestinal disorders | 1/6 | 3/3 | 1/3 | 2/3 | 5/8 | 3/3 | 3/7 | 5/6 | 5/6 | 6/18 | 0/7 |
| AstheniaGeneral disorders | 6/6 | 3/3 | 2/3 | 3/3 | 8/8 | 3/3 | 5/7 | 2/6 | 3/6 | 13/18 | 2/7 |
| FolliculitisInfections and infestations | 4/6 | 3/3 | 0/3 | 2/3 | 4/8 | 1/3 | 4/7 | 2/6 | 3/6 | 0/18 | 0/7 |
| RhinitisInfections and infestations | 3/6 | 1/3 | 3/3 | 3/3 | 4/8 | 2/3 | 1/7 | 0/6 | 2/6 | 5/18 | 1/7 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 1/3 | 1/3 | 1/3 | 2/8 | 3/3 | 1/7 | 3/6 | 3/6 | 1/18 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 1/3 | 1/3 | 0/3 | 2/8 | 3/3 | 1/7 | 2/6 | 1/6 | 1/18 | 2/7 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 | 3/3 | 1/3 | 2/3 | 3/8 | 3/3 | 4/7 | 6/6 | 4/6 | 11/18 | 2/7 |
Treated Set (TS): A treated set (TS) was defined consisting of all patients who received at least one dose of nintedanib or afatinib during the study period.
| Age, Continuous(years) | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.7 ± 8.1 | 51.7 ± 1.5 | 46.7 ± 4.9 | 53.3 ± 11.0 | 51.5 ± 9.7 | 44.3 ± 8.1 | 64.9 ± 3.5 | 52.2 ± 6.0 | 63.3 ± 10.3 | 58.1 ± 10.9 | 58.1 ± 6.8 | 56.0 ± 9.7 |
| Sex: Female, Male(Participants) | Nintedanib 150 mg +Afatinib 30 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Continuously | Nintedanib 200 mg +Afatinib 10 mg - Continuously | Nintedanib 200 mg +Afatinib 20 mg - Continuously | Nintedanib 200 mg +Afatinib 30 mg - Continuously | Nintedanib 200 mg +Afatinib 40 mg - Continuously | Nintedanib 150 mg +Afatinib 40 mg - Intermittently | Nintedanib 200 mg +Afatinib 30 mg - Intermittently | Nintedanib 200 mg +Afatinib 40 mg - Intermittently | NSCLC | Pancreatic Adenocarcinoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 0 | 1 | 6 | 2 | 0 | 4 | 2 | 11 | 1 | 31 |
| Male | 3 | 2 | 3 | 2 | 2 | 1 | 7 | 2 | 4 | 7 | 6 | 39 |
The record gives a start of Oct 2009, a primary completion of Dec 2012 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Afatinib · Nintedanib